288 related articles for article (PubMed ID: 30113428)
21. TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia.
Greco SH; Tomkötter L; Vahle AK; Rokosh R; Avanzi A; Mahmood SK; Deutsch M; Alothman S; Alqunaibit D; Ochi A; Zambirinis C; Mohaimin T; Rendon M; Levie E; Pansari M; Torres-Hernandez A; Daley D; Barilla R; Pachter HL; Tippens D; Malik H; Boutajangout A; Wisniewski T; Miller G
PLoS One; 2015; 10(7):e0132786. PubMed ID: 26172047
[TBL] [Abstract][Full Text] [Related]
22. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
23. Orthotopic model of human pancreatic ductal adenocarcinoma and cancer cachexia in nude mice.
Jones-Bolin S; Ruggeri B
Curr Protoc Pharmacol; 2007 Jun; Chapter 14():Unit 14.3. PubMed ID: 21948162
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
25. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer.
Zhou Z; Ren Y; Yang J; Liu M; Shi X; Luo W; Fung KM; Xu C; Bronze MS; Zhang Y; Houchen CW; Li M
Gastroenterology; 2022 Nov; 163(5):1281-1293.e1. PubMed ID: 35777482
[TBL] [Abstract][Full Text] [Related]
26. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.
Togashi Y; Kogita A; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Kitano M; Okuno K; Kudo M; Nishio K
Cancer Lett; 2015 Jan; 356(2 Pt B):819-27. PubMed ID: 25449777
[TBL] [Abstract][Full Text] [Related]
27. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.
Ozola Zalite I; Zykus R; Francisco Gonzalez M; Saygili F; Pukitis A; Gaujoux S; Charnley RM; Lyadov V
Pancreatology; 2015; 15(1):19-24. PubMed ID: 25524484
[TBL] [Abstract][Full Text] [Related]
28. Waste management - cytokines, growth factors and cachexia.
Saini A; Al-Shanti N; Stewart CE
Cytokine Growth Factor Rev; 2006 Dec; 17(6):475-86. PubMed ID: 17118696
[TBL] [Abstract][Full Text] [Related]
29. A TGF-β pathway associated with cancer cachexia.
Guttridge DC
Nat Med; 2015 Nov; 21(11):1248-9. PubMed ID: 26540384
[TBL] [Abstract][Full Text] [Related]
30. [Systemic and local mechanisms leading to cachexia in cancer].
Grabiec K; Burchert M; Milewska M; Błaszczyk M; Grzelkowska-Kowalczyk K
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1397-409. PubMed ID: 24493689
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.
Fearon KC; Barber MD; Falconer JS; McMillan DC; Ross JA; Preston T
World J Surg; 1999 Jun; 23(6):584-8. PubMed ID: 10227928
[TBL] [Abstract][Full Text] [Related]
32. Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention.
Shum AM; Polly P
Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):247-59. PubMed ID: 22385113
[TBL] [Abstract][Full Text] [Related]
33. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia.
Barber MD; Fearon KC; Tisdale MJ; McMillan DC; Ross JA
Nutr Cancer; 2001; 40(2):118-24. PubMed ID: 11962246
[TBL] [Abstract][Full Text] [Related]
34. Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients.
Brown TT; Zelnik DL; Dobs AS
Int J Gastrointest Cancer; 2003; 34(2-3):143-50. PubMed ID: 15361649
[TBL] [Abstract][Full Text] [Related]
35. Prevention and treatment of cancer cachexia: new insights into an old problem.
Muscaritoli M; Bossola M; Aversa Z; Bellantone R; Rossi Fanelli F
Eur J Cancer; 2006 Jan; 42(1):31-41. PubMed ID: 16314085
[TBL] [Abstract][Full Text] [Related]
36. Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer.
Dasgupta A; Arneson-Wissink PC; Schmitt RE; Cho DS; Ducharme AM; Hogenson TL; Krueger EW; Bamlet WR; Zhang L; Razidlo GL; Fernandez-Zapico ME; Doles JD
JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34874916
[TBL] [Abstract][Full Text] [Related]
37. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Pretto F; Ghilardi C; Moschetta M; Bassi A; Rovida A; Scarlato V; Talamini L; Fiordaliso F; Bisighini C; Damia G; Bani MR; Piccirillo R; Giavazzi R
Oncotarget; 2015 Feb; 6(5):3043-54. PubMed ID: 25460504
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a cancer cachectic factor.
Todorov P; Cariuk P; McDevitt T; Coles B; Fearon K; Tisdale M
Nature; 1996 Feb; 379(6567):739-42. PubMed ID: 8602222
[TBL] [Abstract][Full Text] [Related]
39. Diabetes increases mortality in patients with pancreatic and colorectal cancer by promoting cachexia and its associated inflammatory status.
Chovsepian A; Prokopchuk O; Petrova G; Gjini T; Kuzi H; Heisz S; Janssen KP; Martignoni ME; Friess H; Hauner H; Rohm M
Mol Metab; 2023 Jul; 73():101729. PubMed ID: 37094629
[TBL] [Abstract][Full Text] [Related]
40. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer.
Babic A; Rosenthal MH; Sundaresan TK; Khalaf N; Lee V; Brais LK; Loftus M; Caplan L; Denning S; Gurung A; Harrod J; Schawkat K; Yuan C; Wang QL; Lee AA; Biller LH; Yurgelun MB; Ng K; Nowak JA; Aguirre AJ; Bhatia SN; Vander Heiden MG; Van Den Eeden SK; Caan BJ; Wolpin BM
Nat Commun; 2023 Jul; 14(1):4317. PubMed ID: 37463915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
